Form 4: Vera Therapeutics Officer Exercises Options, Sells Shares

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, exercised stock options and subsequently sold 10,000 shares of Class A Common Stock under a pre-arranged trading plan.

Summary

• William D. Turner, Chief Regulatory Officer of Vera Therapeutics, Inc. (VERA), engaged in a series of transactions on December 8, 2025.
• Turner exercised 10,000 stock options at an exercise price of $15.53 per share.
• Concurrently, Turner sold 10,000 shares of Class A Common Stock at a weighted average price of $45.3053 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Turner on February 20, 2025.
• The shares were sold in multiple transactions at prices ranging from $45.00 to $45.59.
• Following these transactions, Turner beneficially owns 22,500 shares of Class A Common Stock directly.
• Turner also beneficially owns 255,000 derivative securities in the form of stock options.
• The stock options have a vesting schedule where 1/4 of the shares vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (exercise of options and sale of shares) under a Rule 10b5-1 plan. Such transactions are generally neutral in sentiment as they typically do not reflect new information about the company's operational performance or future prospects.

Positives

• The officer monetized vested stock options, indicating a realization of value from their compensation package.
• The sale was conducted under a Rule 10b5-1 trading plan, suggesting a pre-planned transaction rather than a reaction to new, non-public information.

Negatives

• An insider selling shares, even if pre-planned, can sometimes be perceived negatively by the market, though the impact is typically minimal for routine 10b5-1 sales.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction. It does not typically signal a change in company fundamentals, but some investors may view insider selling, even if pre-planned, with slight caution.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares by a Chief Regulatory Officer. Such routine transactions, executed under a Rule 10b5-1 plan, typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Investors should focus on the company's broader financial performance and strategic developments rather than this specific insider activity.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Trading, Stock Options, Share Sale, William D. Turner, Chief Regulatory Officer, 10b5-1 Plan